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Edited by Beat ImhofAbstract The co-signaling molecule B7-H1 (CD274) functions
as both a co-inhibitor through programmed death-1 (PD-1)
receptor and a co-stimulator via an as-yet-unidentiﬁed receptor
on T cells. We investigated the physiological role of endogenous
B7-H1 in the pathogenesis of herpetic stromal keratitis (HSK)
caused by herpes simplex virus type 1 (HSV-1). Following
HSV-1 infection of the cornea of mice, B7-H1 expression was
up-regulated in the CD11b+ macrophage population in the drain-
ing lymph nodes (dLN) and in the inﬂamed cornea. In addition,
HSV-1 infection signiﬁcantly increased PD-1 expression on
CD4+ T cells in the dLN and inﬂamed cornea. The administra-
tion of antagonistic B7-H1 monoclonal antibody resulted in the
proliferation of HSV-speciﬁc CD4+ T cells that secreted inter-
feron (INF)-c, and inhibited the apoptosis of HSV-speciﬁc
CD4+ T cells, which exaggerated HSK. These results strongly
suggest that the B7-H1 may be involved in suppression of the
development of HSK.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Following an initial infection of the cornea of humans with
herpes simplex virus type 1 (HSV-1), the virus enters nerve ter-
minals in the corneal epithelium, is transported retrogradely to
neuronal cell bodies within the superior cervical and trigeminal
ganglia, and then becomes latent [1,2]. Recurrent reactivation
of latent HSV-1 triggers repeated inﬂammation and scarring in
the stromal layer of the cornea; this leads to progressive cor-
neal opacity and neovascularization, which is referred to as
herpetic stromal keratitis (HSK) [3]. In a mouse model of
HSK, two distinct episodes of corneal inﬂammation occur fol-Abbreviations: HSV, Herpes simplex virus; HSK, herpetic stromal
keratitis; PD-1, programmed death-1; mAb, monoclonal antibody
*Corresponding author. Fax: +82 51 891 6004.
E-mail address: miccih@inje.ac.kr (I.-H. Choi).
1 These authors contributed equally to this work.
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.09.098lowing HSV-1 infection: the ﬁrst episode is transient, usually
subsides within two days of the initial infection, and is caused
by the replication of HSV-1 within corneal epithelial cells [4].
Severe inﬂammation occurs subsequently at approximately se-
ven days postinfection (p.i.) within the stromal layer of the cor-
nea in the absence of replicating virus, and this process is
mediated mainly by HSV-1-speciﬁc CD4+ T cells that produce
Th1 cytokines including IFN-c and interleukin (IL)-12 [5]. This
CD4+ T cell population is believed to be responsible for the
inﬁltration of neutrophils and tissue destruction, which leads
to the development of HSK [6]. Interestingly, HSV-speciﬁc
CD8+ T cells are thought to be involved in ocular virus clear-
ance rather than in lesion development [7].
It is well established that the activation of naı¨ve T cells re-
quires two signals from antigen-presenting cells; the antigen-
speciﬁc signals, which is transmitted through T cell receptors
(TCRs) in conjunction with major histocompatibility complex
(MHC) loaded with antigenic peptides, and the antigen-non-
speciﬁc signals through CD28 or cytotoxic T lymphocyte anti-
gen-4 (CTLA-4) on T cells via engagement with the B7 co-
signaling family including B7-1 (CD80) and B7-2 (CD86) [8].
Among the antigen-presenting cells in the cornea, dendritic
cells such as Langerhans cells, which are widely believed to
be essential for the activation of HSV-1-speciﬁc CD4+ T cells,
engulf viral particles in the cornea and then migrate to drain-
ing lymph nodes (dLNs) where these cells present viral pep-
tides to antigen-speciﬁc CD4+ T cells [9]. Some reports have
suggested that the regulation of pathogenic CD4+ T cells by
co-signaling molecules mediates the pathogenesis of HSK.
The observation that blocking the endogenous B7-1 expression
in the inﬂamed cornea prevented HSK development indicated
that an interaction between B7-1 and CD28 might be involved
in the pathogenesis of HSK [10]. In addition to B7-1, members
of the family of tumor necrosis factor (TNF) receptors, includ-
ing CD137 (4-1BB) and CD154 (CD40L), have been impli-
cated in the regulation of HSK. For example, knockout mice
for each of the aforementioned molecules exhibited a reduction
in HSK and reduced Th1 responses to HSV-1, respectively
[11,12].
B7-H1 (PD-L1), a member of the B7 family, could be stimula-
tory or inhibitory for T cell immune responses through engage-
ment of diﬀerent receptors as well as reverse signaling of B7-H1
toward T cells [13,14]. Growing body of in vivo evidence sug-
gests that endogenous B7-H1 plays suppressive functions inblished by Elsevier B.V. All rights reserved.
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hypersensitivity [18] through its cognate receptor, programmed
death-1 (PD-1), on activated T cells by inducing apoptosis of
eﬀector T cells. On the other hand, B7-H1 is also reported to
stimulate T cell immune response through an as-yet-unidentiﬁed
co-stimulatory receptor(s) on T cells, as suggested by the ﬁnding
that B7-H1 expression on b-islet cells promoted graft rejection
[19]. Few studies have addressed the role of endogenous B7-
H1 in viral infections, except for one report that suggested that
B7-H1 expression was involved in T cell hyporesponsiveness in
human immunodeﬁciency virus (HIV) patients [20].
In this study, we investigated the physiological role of
endogenous B7-H1 in HSK. Our ﬁndings demonstrate that
the B7-H1 suppresses the eﬀector CD4+ Th1 cells that are spe-
ciﬁc for HSV-1 by inhibiting proliferation, promoting apopto-
sis, and diminishing IFN-c production of HSV-1-speciﬁc
CD4+ T cells. Therefore, B7-H1 might act as a co-inhibitor
in the development of HSK.2. Materials and methods
2.1. Mice and viral infection
BALB/c (H-2d) mice were obtained from Charles River Laboratories
(Yokohama, Japan). All mice were housed and cared for in accordance
with institutional guidelines. The RE strain of HSV-1 was grown on
Vero cells (ATCC CCL81, Rockville, MD) in minimal essential med-
ium supplemented with 2% heat-inactivated fetal bovine serum (Hy-
clone, Logan UT), penicillin (100 U/ml), and streptomycin (100 lg/
ml). The titration of viral stock by plaque assay involved the infection
of permissive Vero cells with serially diluted culture supernatant that
contained HSV-1. Virus stocks were stored in aliquots at 70 C.
2.2. Antibodies
Antagonistic mouse B7-H1 monoclonal antibody (mAb) (10B5)
raised in hamster and isotypic control hamster anti-DNP (UC8-1B9)
mAb were puriﬁed from ascites using protein G columns (Sigma, St.
Louis, MO). The speciﬁcity of 10B5 was tested using spleen cells that
were stimulated with lipopolysaccharide (5 lg/ml for 24 h) or a mouse
B7-H1 transfectant of 293 cells. We reported previously that the eﬀect
of B7-H1 mAb on blocking an interaction between B7-H1 and PD-1
was observed in an experimental setting where the binding of B7-H1
Ig to EL4 cells expressing PD-1 was completely inhibited by B7-H1
mAb [21]. Furthermore, in vivo administration of 10B5 mAb into
tumor-bearing mice signiﬁcantly regresses tumor growth [21]. The fol-
lowing mAbs were used. Fluorescein isothiocyanate (FITC)-conju-
gated anti-mouse CD4 (GK1.5), FITC-conjugated anti-mouse CD8a
(53-6.7), and FITC-conjugated anti-mouse CD11b (M1/70) were ob-
tained from DiNonA (Seoul, Korea). Phycoerythrin (PE)-conjugated
anti-mouse PD-1 (J43), PE-conjugated anti-mouse CD62L (MEL-
14), FITC-conjugated anti-5-bromo-2-deoxyuridine (BrdU), puriﬁed
anti-mouse CD16/CD32 (2.4G2), biotin-conjugated hamster IgG1
(A19-3), and FITC-conjugated Annexin V were purchased from BD
Bioscience (San Diego, CA). PE-conjugated streptavidin was obtained
from Jackson Immunolaboratories (West Grove, PA).
2.3. HSV-1 infection, HSK scoring, and administration of antibodies
All mice were subjected to corneal infection under anesthesia with
ketamine hydrochloride (1 mg/kg) and xylazine (0.5 mg/kg). First, cor-
neas were scratched gently with a 27 gauge needle in a criss-cross pat-
tern before 1 · 105 pfu of the HSV-1 RE was applied topically. The
eyes were examined with a slit lamp biomicroscope (Kowa, Japan) at
various days p.i. and were scored as follows: 0, normal cornea; 1.0+,
edema, mild opacity, and neovascularization; 2.0+, edema, moderate
opacity, and neovascularization; 3.0+, severe edema, opacity, neovas-
cularization, and iris not visible; 4.0+, corneal perforation. To block
endogenous B7-H1, antagonistic B7-H1 mAb (10B5) or isotypic con-
trol hamster IgG (200 lg each) was administered intraperitoneally on
the day before and 2 days after infection. In vivo administration of
10B5 did not deplete any cell population (Data not shown).2.4. Flow cytometry
To detect B7-H1 and PD-1 expression on T cells and macrophages,
cells were ﬁrst incubated with FcR blocker (2.4G2) and were stained
subsequently with biotin-conjugated anti-mouse B7-H1. B7-H1 was
detected with PE-conjugated streptavidin and FITC-conjugated
mAbs speciﬁc for CD4, CD8, or CD11b. PD-1 was detected with
PE-conjugated anti-mouse PD-1 and FITC-conjugated CD4 or CD8.
To examine the T cell phenotype, cells were stained with FITC-
conjugated anti-mouse CD4 and PE-conjugated anti-mouse CD62L.
Analyses were performed using ﬂow cytometry (FACSort and Cell-
QuestPro software, BD Bioscience, San Diego, CA). To stain prolifer-
ating cells that were speciﬁc for HSV-1, dLN cells (2 · 105) were
restimulated in vitro with ultraviolet (UV)-inactivated HSV-1
(1 · 108 pfu) for three days. Cells were treated with 10 lM BrdU for
the last 1 h. Cells were ﬁrst stained with a cell-surface marker before
being ﬁxed and permeabilized with the BD Cytoﬁx/Cytoperm kit (BD
Bioscience) according to the manufacturers instructions. Proliferating
cells were detected by staining with FITC-conjugated anti-BrdU mAb
(BD Bioscience). To stain apoptotic cells, dLN cells were suspended
in Annexin V binding buﬀer (BD Bioscience), and were stained with
PE-conjugated anti-mouse CD4 and FITC-conjugated Annexin V.
For the staining of intracellular IFN-c, cells were ﬁrst stained with
cell surface markers, and subsequently ﬁxed, permeabilized with the
Cytoﬁx/Cytoperm Kit (BD Bioscience), according to the manufac-
turers instructions, and incubated with PE-conjugated anti-IFN-c
mAb.
2.5. Isolation of inﬁltrating cells from the corneal stroma
Infected corneas were removed under aseptic conditions and were
cut into small pieces before being incubated with 100 U/ml collagenase
type IV (Sigma, St. Louis, MO) for 60 min at 37 C in a humidiﬁed
atmosphere with 5% CO2. Thereafter, the tissue fragments were dis-
rupted by grinding, and a single-cell suspension was obtained by pass-
ing the ground tissue through a cell strainer (BD Falcon, Bedford,
MA). Cells were then washed with phosphate-buﬀered saline.
2.6. Cell proliferation and cytokine assays
CD4+ T cells from cervical lymph nodes were isolated using anti-
CD4 magnetic beads (Miltenyl Biotech, Auburn, CA) at day 7 p.i.
Cells (2 · 105) according to the manufacturers instruction. Cells were
cocultured with syngeneic spleen cells (2 · 105) pulsed with UV-inacti-
vated HSV-1 for 3 days at 37 C under 5% CO2, and were then pulsed
with 1 lCi [3H] thymidine (Amersham Biosciences, Piscataway, NJ) for
the last 12 h. The incorporation of [3H] thymidine was measured with a
b-counter (Wallac, Torrance, CA). The concentrations of IFN-c and
IL-4 within the cell culture supernatant were measured using an en-
zyme-linked immunosorbent assay (ELISA) according to the manufac-
turers speciﬁcations (e-Bioscience). Optical densities were measured at
450 nm with an ELISA plate reader (Molecular Devices, USA). In an
experiment concerning an apoptotic phenotype of T cells in the pres-
ence of B7-H1 transfectant, T cells were isolated from spleen and
lymph nodes of naı¨ve Balb/c mice using anti-CD90 (Thy1.2) magnetic
beads according to the manufacturers instruction. Cells (2 · 105) were
cocultured with B7-H1- or mock-transfectants (2 · 105) in the presence
or absence of anti-mouse CD3 (1 lg/ml, 145.2C11) plus anti-B7-H1
(10 lg/ml) or control Ig for three days at 37 C under 5% CO2. Cells
were stained with FITC-conjugated Annexin V and analyzed by ﬂow
cytometry.
2.7. Statistical analysis
Data obtained were analyzed for statistical signiﬁcance by a one-
tailed Students t test.3. Results and discussion
3.1. Expression of B7-H1 and PD-1 following HSV-1 infection
B7-H1 expression is detectable in resting T cells, B cells,
macrophages, and dendritic cells, and is upregulated in these
cells following stimulation with inﬂammatory cytokines
including interferon (INF)-c [22,23]. The expression of PD-1
on activated T cells can be induced in vitro and in vivo
H. Jun et al. / FEBS Letters 579 (2005) 6259–6264 6261[24,25]. As B7-H1 mediates a negative regulation of eﬀector T
cells via PD-1, we examined the expression of B7-H1 and PD-1
on T cells following HSV-1 infection of the mouse corneas. We
found that PD-1 expression was detectable at a low level in
both CD4+ and CD8+ T cells from uninfected mice. However,
after HSV-1 infection, PD-1 expression was upregulated pre-
dominantly on CD4+ T cells in the dLN. PD-1 expression in
CD4+ T cells peaked at day 7 p.i. (18.8 ± 2.3% increase on to-
tal CD4+ T cells versus 6.6 ± 1.5% on total CD8+ T cells)
(Fig. 1A). The number of B7-H1-expressing macrophages in-
creased in dLNs following HSV-1 infection, and peaked at
day 5 p.i. (Fig. 1A). Collectively, these results suggested that
the interaction between B7-H1 and PD-1 might be crucial
for the priming of HSV-1-speciﬁc CD4+ T cells in the dLN.
It is well established that HSV-1-speciﬁc CD4+ T cells are
essential for regulating inﬂammation in the virus-infected cor-
nea [reviewed in [3]]. Consistent with this idea, we found that T
cells isolated from inﬂamed corneas at day 13–17 p.i. (severity
scores: 1.0–3.0) contained mainly CD4+ T cells, more than
50% of which expressed PD-1. Additionally, B7-H1 expression
was greatly upregulated in 90% of the inﬁltrated CD11b+
macrophages (Fig. 1B). These observations suggest that B7-
H1 might be involved in the regulation of activated CD4+ T
cells in inﬂamed cornea via PD-1 signaling.
3.2. Blockade of B7-H1 enhances HSK
Having known that 10B5 inhibits the interaction between
B7-H1 and PD-1 in our previous report [21], we decided to
examine the eﬀect of 10B5 on blocking apoptosis. As shown
in Fig. 2A, P815 transfectant expressing B7-H1 signiﬁcantly in-
creased the T cell apoptosis in the presence of anti-CD3. How-
ever, the apoptosis was signiﬁcantly reduced in the presence of
10B5. To investigate whether the B7-H1 engagement was in-
volved in the development of HSK, we administrated antago-Fig. 1. Expression of programmed death-1 (PD-1) and B7-H1 on immune cell
mice. Corneas of BALB/c mice were infected with the RE strain of herpes sim
indicated time points from cervical dLNs and were stained with anti-CD4 o
antibodies, and were analyzed by ﬂow cytometry. (B) Inﬁltrating cells were is
CD4 and anti-PD-1 antibodies or anti-CD11b and anti-B7-H1 antibodies. Th
representative of three independent experiments.nistic B7-H1 mAb to mice that had been infected with HSV-1
and compared the severity of HSK with that of control mice
given isotypic control antibodies.
In B7-H1 mAb-treated mice, HSK developed more rapidly
(P = 0.018 at day 8 p.i.) and was more severe than in the con-
trol mice throughout the indicated days after HSV-1 infection
(mean maximal severity scores = 3.1 ± 0.8 and 2.0 ± 0.7 in B7-
H1 mAb-treated and control mice, respectively; P = 0.014).
Therefore, our results suggest that the interaction between
B7-H1 and PD-1may be important in the development of
HSK. However, the fact that the incidence of HSK among
the HSV-1-infected mice was not signiﬁcantly diﬀerent
between the experimental groups left untreated or treated with
B7-H1 mAb (60% in both groups; data not shown) suggest
that B7-H1 is more likely involved in negative regulation at
the eﬀector phase of T cell activation rather than at the prim-
ing phase.
3.3. Blockade of B7-H1 activates pathogenic CD4+ T cells
Having determined that B7-H1 inhibited the development of
HSK, we explored the mechanism that underlies the acceler-
ated HSK in mice that were given B7-H1 mAb by examining
the role of B7-H1 in the HSV-1-speciﬁc T cell response. First,
we investigated the eﬀect of endogenous B7-H1 on the activa-
tion of HSV-1-speciﬁc CD4+ T cells by blocking B7-H1 with
the antagonistic mAb. While the blockade of B7-H1 caused
a slight increase of CD4+ T cells that expressed a CD62Llow/
activation marker at day 7 p.i. (9.4 ± 1.4% in B7-H1 mAb-
treated mice versus 6.7 ± 1.2% in controls) (Fig. 3A), the
proportion of HSV-1-speciﬁc CD4+ T cells increased twofold
in the BrdU incorporation assay (4.5 ± 1.0% in B7-H1 mAb-
treated mice versus 2.3 ± 0.8% in controls) (Fig. 3B). A simi-
lar signiﬁcant increase of HSV-1-speciﬁc CD4+ T cells in
B7-H1 mAb-treated mice was observed in the [3H] thymidines from the draining lymph nodes (dLN) and inﬂamed corneal stroma of
plex virus type 1 (HSV-1) (1 · 105 pfu). (A) Cells were collected at the
r anti-CD8 and anti-PD-1 antibodies, or anti-CD11b and anti-B7-H1
olated from inﬂamed corneas at day 15 p.i. and were stained with anti-
e histogram was generated by gating CD4+ or CD11b+ cells. Data are
Fig. 2. Blockade of B7-H1:PD-1 accelerated the development of herpetic stromal keratitis (HSK). (A) Blocking properties of anti-B7-H1. T cells
were cocultured with B7-H1- or mock- transfectants in the indicated conditions for three days. Cells were stained with Annexin V and analyzed by
ﬂow cytometry. (B) Mice were infected with HSV-1 as described in the legend of Fig. 1. B7-H1 mAb or an isotypic control antibody (200 lg each) was
administered intraperitoneally one day before and two days after infection. The severity of HSK was graded according to the degree of corneal
opacity and neovascularization (see Section 2). Data are the mean ± S.E.M. severity of HSK. For both groups, n = 20 corneas from 10 mice that
developed HSK. Similar results were obtained from two independent experiments. \, P < 0.05; \\, P < 0.01 (compared with control group).
Fig. 3. Blockade of B7-H1 enhanced HSV-1-speciﬁc eﬀector T cell responses. Mice were infected with HSV-1 as described in the legend of Fig. 1.
Cells were isolated from dLNs at day 7 p.i. (A) dLN cells were stained with FITC-conjugated anti-CD4 and PE-conjugated anti-CD62L antibodies
and were analyzed by ﬂow cytometry. (B,C) dLN cells (2 · 105) were restimulated with ultraviolet (UV)-inactivated HSV-1 RE (1 · 108 pfu) for three
days and were analyzed using a 5-bromo-2-deoxyuridine (B) or [3H] thymidine (C) incorporation assay. (D) To detect apoptotic cells, dLN cells were
stained with anti-CD4 and anti-Annexin V antibodies after in vitro restimulation with UV-inactivated HSV-1. \\, P < 0.01 (compared with control
group).
6262 H. Jun et al. / FEBS Letters 579 (2005) 6259–6264incorporation assay (P = 0.0035, Fig. 3C). These results sug-
gest that the blockade of the B7-H1 engagement results in
the expansion of HSV-1-speciﬁc CD4+ T cell population.
Because PD-1 induces apoptosis upon engagement with cog-
nate ligands B7-H1 and B7-DC, and cross-linking antibodies
[22,26], we tested whether the blockade of B7-H1 would pre-
vent apoptosis of virus-speciﬁc T cells. Since there is no infor-
mation about MHC class II – restricted peptides of HSV-1
required for the activation of CD4+ T cells, we stimulateddLN cells with UV-irradiated HSV-1 in our experimental set-
ting. We found that CD4+ T cells from HSV-1-infected mice
given B7-H1 mAb showed an increased rate of survival com-
pared to CD4+ T cells from the control mice (Annexin V-posi-
tive CD4+: 26.8 ± 1.2% in B7-H1 mAb-treated mice versus
32.4 ± 1.7% in controls) (Fig. 3D). While this result does not
indicate that how many HSV-1-speciﬁc CD4+ T cells become
resistant to apoptosis under B7-H1 blockade, the data clearly
demonstrate that blocking of B7-H1 engagement of PD-1
Fig. 4. Blockade of B7-H1 enhanced CD4+ Th1 responses. Mice were infected with HSV-1 as described in the legend of Fig. 1. Cells were isolated
from dLNs at day 7 p.i. CD4+ and CD8+ T cells were restimulated with UV-inactivated HSV-1 for 72 h. (A) Intracellular IFN-c was detected by ﬂow
cytometry. (B) The culture supernatants were collected and were analyzed for interferon (INF)-c and interleukin (IL)-4 productions using an enzyme-
linked immunosorbent assay (ELISA). \\, P < 0.01 (compared with control group).
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tion. Taken together, the fact that the blockade of B7-H1
augmented proliferation and inhibited apoptosis of HSV-
1-virus-speciﬁc CD4+ T cells indicates that, during HSV-1
infection, B7-H1 suppresses T cell immunity through its
co-inhibitory receptor, PD-1, rather than enhanced T cell re-
sponse via an as-yet unidentiﬁed co-stimulatory receptor(s).
3.4. Blockade of B7-H1 enhances activation of CD4+ Th1 cells
As eﬀector CD4+ Th1 cells contribute to the immunopathol-
ogy of HSK [3], we examined whether the blockade of B7-H1
would inﬂuence the eﬀector CD4+ Th1 cell response to HSV-1.
CD4+ T cells isolated from dLNs of mice given B7-H1 mAb at
day 7 p.i. produced IFN-c about twice more than CD4+ T
cells from the control mice upon being restimulated with
UV-inactivated HSV-1, as evidenced by an intracellular stain-
ing (7.1 ± 0.4% in B7-H1 mAb-treated mice versus 3.1 ± 1.2%
in controls, Fig. 4A) and ELISA (P = 0.005, Fig. 4B). In the
same experimental setting, as expected, we found that CD8+
T cells produced much less IFN-c than CD4+ T cells from mice
given B7-H1 mAb (7.1 ± 1.1% in CD4+ T cells versus
0.9 ± 0.1% in CD8+ T cells). There was no diﬀerence of intra-
cellular IFN-c production between CD8+ T cells from the two
groups as well (0.9 ± 0.1% in B7-H1 mAb-treated mice versus
0.8 ± 0.2% in controls) (Fig. 4A). In addition, we found that
there was no detectable production of IL-4 in CD4+ Th1 cells
in either of the two groups (Fig. 4B). In agreement with the
previous studies in which the blockade of the B7-H1:PD-1
pathway rapidly precipitated diabetes in non-obese diabetic
mice by inducing IFN-c-producing autoreactive T cells, ourdata indicate that endogenous B7-H1 during HSV-1 infection
may suppress the proliferation of IFN-c-producing eﬀector
CD4+ Th1 cells speciﬁc for HSV-1.
We surmise that B7-H1 expressed on macrophages that
inﬁltrate the inﬂamed cornea may preferentially inhibit IFN-
c-producing CD4+ Th1 cells speciﬁc for HSV-1 through B7-
H1:PD-1 signaling. However, because inﬁltrated CD4+ T cells
also expressed B7-H1 (data not shown), we cannot exclude the
possibility that PD-1 engagement is mediated by B7-H1 ex-
pressed on T cells through T cell-to-T cell interactions, which
would lead to the suppression of PD-1-expressing eﬀector T
cells. Collectively, the results of the present study have revealed
a novel co-inhibitory role for B7-H1 against HSV-1 infection
in vivo.
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